Case number 2015-1460
Astrazeneca AB v. Mylan Pharmaceuticals Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jan 10, 2017 | 126 | The petition for writ of certiorari, [16-360], filed on 09/19/2016, was Denied on 01/09/2017. [397584] [15-1456, 15-1460] [CAB] [Entered: 01/10/2017 03:30 PM] (1) |
| Sep 26, 2016 | 125 | Petition for writ of Certiorari filed on 09/19/2016 in the Supreme Court of the United States. Supreme Court #: 16-360, Mylan Pharmaceuticals Inc. v. Acorda Therapeutics Inc. [369199] [15-1456, 15-1460] [CAB] [Entered: 09/26/2016 12:37 PM] (1) |
| Jun 27, 2016 | 124 | Mandate issued to the United States District Court for the District of Delaware. Service as of this date by Clerk of Court. [346702] [CAB] [Entered: 06/27/2016 02:16 PM] (2) |
| Jun 20, 2016 | 123 | ORDER filed denying [327283-2] petition for en banc rehearing filed by Mylan Pharmaceuticals Inc. and Mylan Inc. in 15-1456, and denying [102] petition for en banc rehearing filed by Mylan Pharmaceuticals Inc. in 15-1460. By: En Banc (Per Curiam). Service as of this date by Clerk of Court. [345103] [15-1456, 15-1460] [CAB] [Entered: 06/20/2016 04:06 PM] (2) |
| May 31, 2016 | 122 | ORDER filed granting motions to withdraw attorney Thomas G. Sprankling [338833-2] in 15-1456 and [121] in 15-1460 filed by Amicus Curiae Pharmaceutical Research and Manufacturers of America. By: Per Curiam. Service as of this date by Clerk of Court. [339357] [15-1456, 15-1460] [CAB] [Entered: 05/31/2016 10:24 AM] (2) |
| May 26, 2016 | 121 | MOTION of Amicus Curiae Pharmaceutical Research and Manufacturers of America to withdraw counsel Thomas G. Sprankling. Response/Opposition is due 06/09/2016 [Consent: unopposed]. Service: 05/26/2016 by email. [338837] [Thomas Sprankling] [Entered: 05/26/2016 04:06 PM] (4) |
| May 20, 2016 | 120 | 18 paper copies of the response [119] received from Appellee Astrazeneca AB. [337503] [CAB] [Entered: 05/23/2016 11:50 AM] (0) |
| May 18, 2016 | 119 | RESPONSE of Appellee Astrazeneca AB to the petition for en banc rehearing [102] filed by Appellant Mylan Pharmaceuticals Inc. in 15-1460. Service: 05/18/2016 by email. [336607] [Kannon Shanmugam] [Entered: 05/18/2016 04:18 PM] (22) |
| May 5, 2016 | 118 | CORRECTED ORDER: correcting court order granting motion for leave to file an amicus curiae brief [114]]; reason(s): to include 15-1456 in the Order. Service as of this date by Clerk of Court. [332404] [15-1456, 15-1460] [CAB] [Entered: 05/05/2016 09:50 AM] (2) |
| May 4, 2016 | 117 | 16 paper copies of the amicus Brief [115] received from Amicus Curiae Generic Pharmaceutical Association. [332262] [AT] [Entered: 05/04/2016 03:41 PM] (0) |
| May 3, 2016 | 114 | ORDER filed granting motion for leave to file an amicus curiae brief in support of Mylan's petition for rehearing en banc [112] filed by Generic Pharmaceutical Association. By: Court (Per Curiam). Service as of this date by Clerk of Court. [331634] [AT] [Entered: 05/03/2016 12:58 PM] (0) |
| May 3, 2016 | 115 | AMICUS BRIEF FILED on Petition for Generic Pharmaceutical Association[113]. Pages: 10. Pursuant to ECF-10(D), the filer is directed to submit the approriate number of copies within two days. [331638] [AT] [Entered: 05/03/2016 01:05 PM] (17) |
| May 3, 2016 | 116 | Corrected Entry of appearance for Wesley E. Weeks as of counsel for Amicus Curiae Generic Pharmaceutical Association. Service: 05/02/2016 by email. [331848] [Wesley Weeks] [Entered: 05/03/2016 04:50 PM] (2) |
| May 2, 2016 | 110 | ORDER filed granting motion to withdraw attorney DAVID ZACHARY HUDSON [330766-2] [109] filed by Appellants Mylan Pharmaceuticals Inc. and Mylan Inc. in 15-1456, and by Appellant Mylan Pharmaceuticals Inc. in 15-1460. By: Court (Per Curiam). Service as of this date by Clerk of Court. [330955] [15-1456, 15-1460] [AT] [Entered: 05/02/2016 08:03 AM] (2) |
| May 2, 2016 | 111 | Entry of appearance for Wesley E. Weeks as of counsel for Amicus Curiae Generic Pharmaceutical Association. Service: 05/02/2016 by email. [331413] [Wesley Weeks] [Entered: 05/02/2016 07:31 PM] (1) |
| May 2, 2016 | 112 | MOTION of Amicus Curiae Generic Pharmaceutical Association for leave to file an amicus curiae brief. Response/Opposition is due 05/16/2016 [Consent: unopposed]. Service: 05/02/2016 by email. [331414] [Wesley Weeks] [Entered: 05/02/2016 07:34 PM] (5) |
| May 2, 2016 | 113 | TENDERED from Amicus Curiae Generic Pharmaceutical Association. Title: AMICUS CURIAE BRIEF. Service: 05/02/2016 by email. [331416] [Wesley Weeks] [Entered: 05/02/2016 07:37 PM] (17) |
| Apr 29, 2016 | 109 | MOTION of Appellant Mylan Pharmaceuticals Inc. to withdraw counsel David Zachary Hudson. Response/Opposition is due 05/12/2016 [Consent: not addressed]. Service: 04/29/2016 by email. [330769] [Paul Clement] [Entered: 04/29/2016 02:05 PM] (4) |
| Apr 22, 2016 | 108 | ORDER filed granting motion to extend time to file a response to en banc/rehearing petition [107] filed by Appellee Astrazeneca AB in 15-1460; extending the time to file a response to the petition for rehearing en banc until 05/18/2016 in 15-1456. By: (Per Curiam). Service as of this date by Clerk of Court. [328718] [15-1460, 15-1456] [SJ] [Entered: 04/22/2016 09:27 AM] (2) |
| Apr 21, 2016 | 107 | MOTION of Appellee Astrazeneca AB to extend the time to file a response to the Petition for Rehearing En Banc until 05/18/2016. Response/Opposition is due 05/05/2016 [Consent: unopposed]. Service: 04/21/2016 by email. [328472] [Kannon Shanmugam] [Entered: 04/21/2016 01:44 PM] (6) |
| Apr 20, 2016 | 105 | The court invites a response from Appellee Astrazeneca AB to the petition for en banc rehearing filed by Appellant in 15-1460. Response is due May 4, 2016. [327938] [AT] [Entered: 04/20/2016 10:17 AM] (1) |
| Apr 20, 2016 | 106 | 18 paper copies of the petition for en banc rehearing [102] received from Appellant Mylan Pharmaceuticals Inc. [327948] [AT] [Entered: 04/20/2016 10:25 AM] (0) |
| Apr 19, 2016 | 103 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re: Appellant's petition for en banc rehearing Docket No. [102], cannot be filed at this time. ERROR: Attorney GEORGE W. HICKS, who appears on the cover and on page 16, has not entered an appearance in this matter. CORRECTION: Attorney HICKS must enter his appearance, or a corrected petition for rehearing may be filed (removing the attorney's name), if received before midnight on the date of this notice. By: Clerk of Court. [327355] [AT] [Entered: 04/19/2016 07:29 AM] (0) |
| Apr 19, 2016 | 104 | Entry of appearance for George W. Hicks, Jr. as of counsel for Appellant Mylan Pharmaceuticals Inc.. Service: 04/19/2016 by email. [327402] [George Hicks] [Entered: 04/19/2016 09:02 AM] (1) |
| Apr 18, 2016 | 102 | Petition for en banc rehearing filed by Appellant Mylan Pharmaceuticals Inc.. Service: 04/18/2016 by email. The paper copies of the petition must be filed within two business days (see ECF-10(d)).The required paper copies should be received by the court on or before 04/20/2016 [327287] [Paul Clement] [Entered: 04/18/2016 04:39 PM] (58) |
| Mar 18, 2016 | 101 | OPINION and JUDGMENT filed. The judgment or decision is: Affirmed. (Precedential Opinion). (For the Court: Newman,Circuit Judge; O'Malley,Circuit Judge and Taranto,Circuit Judge). Opinion concurring in the judgment filed by Circuit Judge O'Malley. [319890] [15-1456, 15-1460] [CAB] [Entered: 03/18/2016 09:14 AM] (38) |
| Mar 14, 2016 | 100 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Appellee Astrazeneca AB. Service: 03/14/2016 by email. [318280] [Kannon Shanmugam] [Entered: 03/14/2016 01:00 PM] (2) |
| Mar 11, 2016 | 98 | NOTICE OF DEFICIENCY: The supplemental authority Document No. [97] filed by Appellant Mylan Pharmaceuticals Inc. in 15-1460 is without proof of service and therefore cannot be accepted for filing at this time. You are being afforded the opportunity to correct the deficiency. At the discretion of the court, the corrected document may be accepted for filing if received before midnight (EST) on the date of this notice. [317678] [AT] [Entered: 03/11/2016 07:48 AM] (0) |
| Mar 11, 2016 | 99 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Appellant Mylan Pharmaceuticals Inc.. Service: 03/11/2016 by email. [317719] [Paul Clement] [Entered: 03/11/2016 09:20 AM] (39) |
| Mar 10, 2016 | 97 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Appellant Mylan Pharmaceuticals Inc.. Service: 03/10/2016 by email. [317631] [Paul Clement] [Entered: 03/10/2016 05:27 PM] (38) |
| Feb 23, 2016 | 96 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Appellee Astrazeneca AB. Service: 02/23/2016 by email. [313438] [Kannon Shanmugam] [Entered: 02/23/2016 09:26 PM] (2) |
| Feb 22, 2016 | 95 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Appellant Mylan Pharmaceuticals Inc.. Service: 02/22/2016 by email. [313027] [Paul Clement] [Entered: 02/22/2016 04:39 PM] (56) |
| Jan 4, 2016 | 94 | Submitted after ORAL ARGUMENT by Paul D. Clement, Esq. for Mylan Pharmaceuticals Inc. and Kannon K. Shanmugam, Esq. for Astrazeneca AB. Panel: Judge: Newman , Judge: O'Malley , Judge: Taranto. [299794] [JAB] [Entered: 01/04/2016 10:36 AM] (0) |
| Dec 11, 2015 | 93 | Response to oral argument order from the Appellant Mylan Pharmaceuticals Inc.. designating Paul D. Clement as arguing attorney. Designated time for argument: 12 minutes. Designated time for rebuttal: 3 minutes. Service of other counsel by Notice of Docket Activity from this entry. [295591] [Paul Clement] [Entered: 12/11/2015 04:04 PM] (0) |
| Nov 24, 2015 | 92 | Response to oral argument order from the Appellee Astrazeneca AB. designating Kannon K. Shanmugam as arguing attorney. Designated time for argument: 15 minutes. Designated time for rebuttal: 0 minutes. Service of other counsel by Notice of Docket Activity from this entry. [291668] [Kannon Shanmugam] [Entered: 11/24/2015 05:08 PM] (0) |
| Nov 20, 2015 | 91 | NOTICE OF CALENDARING. Panel: 1601A. Case scheduled Jan 04, 2016 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, N.W. Washington, DC 20439), Courtroom 201. Response to oral argument order due: 12/15/2015. Counsel should check-in 30 minutes prior to the opening of the session. Please review the Oral Argument Order. [290564] THIS NOTICE APPLIES TO CASE(S): [15-1456, 15-1460] [JAB] [Entered: 11/20/2015 02:51 PM] (0) |
| Oct 27, 2015 | 90 | Notice from Appellant Mylan Pharmaceuticals Inc. regarding conflicts with oral argument (01/06/2016 - 01/08/2016; 02/01/2016 - 02/05/2016). Service: 10/27/2015 by email. [283710] [Paul Clement] [Entered: 10/27/2015 11:47 AM] (4) |
| Sep 8, 2015 | 89 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: Notice regarding the ECF account(s) of Adam Gahtan for Biotechnology Industry Organization. One or more e-mail addresses associated with your CM/ECF account, (achase@whitecase.com), is invalid and has been returned as undeliverable. Pursuant to ECF-2(E) of the Administrative Order Regarding Electronic Case Filing, an ECF filer must update all contact information with the Pacer Service Center. [270109] [IW] [Entered: 09/08/2015 10:00 AM] (0) |
| Sep 4, 2015 | 87 | NOTICE OF DEFICIENCY: The Notice Regarding Conflicts, Document No. [86] filed by Appellant Mylan Pharmaceuticals Inc. in 15-1460 is without a proper/complete proof of service and therefore cannot be accepted for filing at this time. You are being afforded the opportunity to correct the deficiency. CLERK'S NOTE: The required proof of service may be submitted using the ECF event "CORRECTED CERTIFICATE OF SERVICE". At the discretion of the court, the corrected document may be accepted for filing if received before midnight (EST) on the date of this notice. [269713] [AT] [Entered: 09/04/2015 10:42 AM] (0) |
| Sep 4, 2015 | 88 | Notice from Appellant Mylan Pharmaceuticals Inc. regarding conflicts with oral argument (October 5-9, 2015 and December 7-11, 2015). Service: 09/04/2015 by email. [269765] [Paul Clement] [Entered: 09/04/2015 12:03 PM] (2) |
| Sep 3, 2015 | 86 | Notice from Appellant Mylan Pharmaceuticals Inc. regarding conflicts with oral argument (October 5-9, 2015 and December 7-11, 2015). Service: 09/03/2015 by email. [269367] [Paul Clement] [Entered: 09/03/2015 01:29 PM] (1) |
| Aug 18, 2015 | 85 | ORDER granting motion to withdraw attorney [84] filed by Amicus Curiae Chamber of Commerce of the United States of America. Service as of this date by Clerk of Court. [265034] [JW] [Entered: 08/18/2015 09:27 AM] (2) |
| Aug 14, 2015 | 84 | MOTION of Amicus Curiae Chamber of Commerce of the United States of America to withdraw counsel James F. Tierney. Response/Opposition is due 08/27/2015 [Consent: unopposed]. Service: 08/14/2015 by email. [264250] [James Tierney] [Entered: 08/14/2015 12:09 PM] (3) |
| Aug 13, 2015 | 82 | 6 paper copies of the appendix [77] received from Appellant Mylan Pharmaceuticals Inc. and Appellee Astrazeneca AB. [264092] [AT] [Entered: 08/14/2015 07:22 AM] (0) |
| Aug 13, 2015 | 83 | 6 paper copies of the Reply Brief [76] received from Appellant Mylan Pharmaceuticals Inc. [264093] [AT] [Entered: 08/14/2015 07:24 AM] (0) |
| Aug 12, 2015 | 78 | Notice to counsel for Amicus Curiae Biotechnology Industry Organization: The record of this case indicates that the Certificate of Interest has not been filed. A completed certificate of Interest must be submitted in accordance with Fed. Cir. R. 47.4. Service as of this date by Clerk of Court. [263457] [AT] [Entered: 08/12/2015 10:12 AM] (0) |
| Aug 12, 2015 | 79 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.4(a), Fed. Cir. R. 47.3 and ECF-2(E) to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [263459] [AT] [Entered: 08/12/2015 10:12 AM] (0) |
| Aug 12, 2015 | 80 | Certificate of Interest for the Amicus Curiae Biotechnology Industry Organization. Service: 08/12/2015 by email. [263543] [Christopher Glancy] [Entered: 08/12/2015 12:28 PM] (2) |
| Aug 12, 2015 | 81 | Amended Certificate of Interest for the Appellant Mylan Pharmaceuticals Inc.. Service: 08/12/2015 by email. [263707] [Paul Clement] [Entered: 08/12/2015 05:14 PM] (3) |
| Aug 11, 2015 | 75 | TENDERED from Appellant Mylan Pharmaceuticals Inc.. Title: JOINT APPENDIX. Service: 08/11/2015 by email. [263302] [Paul Clement] [Entered: 08/11/2015 03:38 PM] (86) |
| Aug 11, 2015 | 77 | APPENDIX FILED for appellant Mylan Pharmaceuticals Inc. and appellee Astrazeneca AB [75]. Number of Pages: 86. Service: 08/11/2015 by email. Pursuant to ECF-10, filer is directed to file six copies of the appendix in paper format. The paper copies should be received by the court on or before 08/17/2015. [263455] [AT] [Entered: 08/12/2015 10:10 AM] (86) |
| Aug 10, 2015 | 73 | TENDERED from Appellant Mylan Pharmaceuticals Inc.. Title: REPLY BRIEF. Service: 08/10/2015 by email. [263049] [Paul Clement] [Entered: 08/10/2015 03:32 PM] (39) |
| Aug 10, 2015 | 74 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: Notice regarding the ECF account(s) of Mark Pacella for Generic Pharmaceutical Association. One or more e-mail addresses associated with your CM/ECF account, (bdahl@wileyrein.com), is invalid and has been returned as undeliverable. Pursuant to ECF-2(E) of the Administrative Order Regarding Electronic Case Filing, an ECF filer must update all contact information with the Pacer Service Center. [263062] [IW] [Entered: 08/10/2015 03:56 PM] (0) |
| Aug 10, 2015 | 76 | REPLY BRIEF FILED for Appellant Mylan Pharmaceuticals Inc. [73]. Number of Pages: 30. Service: 08/10/2015 by email. Pursuant to ECF-10, filer is directed to file six copies of the brief in paper format. The paper copies of the brief should be received by the court on or before 08/17/2015. [263452] [AT] [Entered: 08/12/2015 10:07 AM] (39) |
| Jul 29, 2015 | 72 | 6 paper copies of the amicus Brief [62] received from Amici Curiae Thomas C. Arthur, Lisa A. Dolak, Richard D. Freer and Megan M. La Belle. [260256] [AT] [Entered: 07/29/2015 12:10 PM] (0) |
| Jul 28, 2015 | 70 | 6 paper copies of the amicus Brief [65] received from Amicus Curiae Pharmaceutical Research and Manufacturers of America. [259880] [AT] [Entered: 07/28/2015 10:46 AM] (0) |
| Jul 28, 2015 | 71 | 6 paper copies of the amicus Brief [64] received from Amicus Curiae Biotechnology Industry Organization. [260165] [AT] [Entered: 07/29/2015 09:56 AM] (0) |
| Jul 27, 2015 | 69 | 6 paper copies of the amicus Brief [63] received from Amicus Curiae Teva Pharmaceuticals USA, Inc. [259640] [AT] [Entered: 07/27/2015 01:26 PM] (0) |
| Jul 24, 2015 | 66 | Certificate of Interest for the Amicus Curiae Pharmaceutical Research and Manufacturers of America. Service: 07/24/2015 by email. [259294] [Kevin Prussia] [Entered: 07/24/2015 01:35 PM] (1) |
| Jul 24, 2015 | 67 | Certificate of Interest for the Amicus Curiae Teva Pharmaceuticals USA, Inc.. Service: 07/24/2015 by email. [259306] [William Jay] [Entered: 07/24/2015 01:55 PM] (2) |
| Jul 24, 2015 | 68 | Certificate of Interest for the Amici Curiae Thomas C. Arthur, Lisa A. Dolak, Richard D. Freer and Megan M. La Belle. Service: 07/24/2015 by email. [259395] [Carter Phillips] [Entered: 07/24/2015 04:24 PM] (2) |
| Jul 23, 2015 | 46 | Entry of appearance for Edmund G. LaCour Jr. as of counsel for Appellant Mylan Pharmaceuticals Inc.. Service: 07/23/2015 by email. [258697] [Edmund LaCour] [Entered: 07/23/2015 09:25 AM] (1) |
| Jul 23, 2015 | 47 | Entry of appearance for Carter G. Phillips as principal counsel for Thomas C. Arthur and Richard D. Freer, Emory University School of Law; Lisa A. Dolak, Syracuse University College of Law; and Megan M. La Belle, Catholic University of America, Columbus School of Law. Service: 07/23/2015 by email. [258869] [Carter Phillips] [Entered: 07/23/2015 02:28 PM] (2) |
| Jul 23, 2015 | 48 | Entry of appearance for Ryan C. Morris as of counsel for Thomas C. Arthur and Richard D. Freer, Emory University School of Law; Lisa A. Dolak, Syracuse University College of Law; and Megan M. La Belle, Catholic University of America, Columbus School of Law. Service: 07/23/2015 by email. [258871] [Carter Phillips] [Entered: 07/23/2015 02:29 PM] (2) |
| Jul 23, 2015 | 49 | Entry of appearance for Anna M. Weinberg as of counsel for Thomas C. Arthur and Richard D. Freer, Emory University School of Law; Lisa A. Dolak, Syracuse University College of Law; and Megan M. La Belle, Catholic University of America, Columbus School of Law. Service: 07/23/2015 by email. [258872] [Carter Phillips] [Entered: 07/23/2015 02:29 PM] (2) |
| Jul 23, 2015 | 50 | TENDERED from Thomas C. Arthur and Richard D. Freer, Emory University School of Law; Lisa A. Dolak, Syracuse University College of Law; and Megan M. La Belle, Catholic University of America, Columbus School of Law Title: AMICUS CURIAE BRIEF. Service: 07/23/2015 by email. [258992] [Carter Phillips] [Entered: 07/23/2015 05:04 PM] (29) |
| Jul 23, 2015 | 51 | Entry of appearance for William M. Jay as principal counsel for Teva Pharmaceuticals USA, Inc.. Service: 07/23/2015 by email. [259001] [William Jay] [Entered: 07/23/2015 05:48 PM] (2) |
| Jul 23, 2015 | 52 | Entry of appearance for Brian T. Burgess as of counsel for Teva Pharmaceuticals USA, Inc.. Service: 07/23/2015 by email. [259002] [Brian Burgess] [Entered: 07/23/2015 05:53 PM] (2) |
| Jul 23, 2015 | 53 | TENDERED from Teva Pharmaceuticals USA, Inc. Title: AMICUS CURIAE BRIEF. Service: 07/23/2015 by email. [259003] [William Jay] [Entered: 07/23/2015 06:05 PM] (34) |
| Jul 23, 2015 | 54 | Entry of appearance for Christopher J. Glancy as principal counsel for BIOTECHNOLOGY INDUSTRY ORGANIZATION. Service: 07/23/2015 by email. [259017] [Christopher Glancy] [Entered: 07/23/2015 07:55 PM] (2) |
| Jul 23, 2015 | 55 | Entry of appearance for Adam R. Gahtan as of counsel for BIOTECHNOLOGY INDUSTRY ORGANIZATION. Service: 07/23/2015 by email. [259018] [Christopher Glancy] [Entered: 07/23/2015 07:58 PM] (2) |
| Jul 23, 2015 | 56 | TENDERED from BIOTECHNOLOGY INDUSTRY ORGANIZATION Title: AMICUS CURIAE BRIEF. Service: 07/23/2015 by email. [259019] [Christopher Glancy] [Entered: 07/23/2015 08:02 PM] (18) |
| Jul 23, 2015 | 57 | Entry of appearance for David W. Ogden as principal counsel for Pharmaceutical Research and Manufacturers of America. Service: 07/23/2015 by email. [259030] [Thomas Saunders] [Entered: 07/23/2015 08:44 PM] (1) |
| Jul 23, 2015 | 58 | Entry of appearance for Thomas G. Saunders as of counsel for Pharmaceutical Research and Manufacturers of America. Service: 07/23/2015 by email. [259031] [Thomas Saunders] [Entered: 07/23/2015 08:47 PM] (1) |
| Jul 23, 2015 | 59 | Entry of appearance for Thomas G. Sprankling as of counsel for Pharmaceutical Research and Manufacturers of America. Service: 07/23/2015 by email. [259033] [Thomas Sprankling] [Entered: 07/23/2015 08:49 PM] (1) |
| Jul 23, 2015 | 60 | Entry of appearance for Kevin S. Prussia as of counsel for Pharmaceutical Research and Manufacturers of America. Service: 07/23/2015 by email. [259034] [Kevin Prussia] [Entered: 07/23/2015 08:51 PM] (1) |
| Jul 23, 2015 | 61 | TENDERED from Pharmaceutical Research and Manufacturers of America Title: AMICUS CURIAE BRIEF. Service: 07/23/2015 by email. [259035] [Kevin Prussia] [Entered: 07/23/2015 08:52 PM] (33) |
| Jul 23, 2015 | 62 | AMICUS BRIEF FILED for Thomas C. Arthur, Richard D. Freer, Lisa A. Dolak, and Megan M. La Belle [50]. Number of Pages: 19. Service: 07/23/2015 by email. Pursuant to ECF-10, filer is directed to file six copies of the brief in paper format. The paper copies of the brief should be received by the court on or before 07/29/2015. [259280] [AT] [Entered: 07/24/2015 01:05 PM] (29) |
| Jul 23, 2015 | 63 | AMICUS BRIEF FILED for Teva Pharmaceuticals USA, Inc. [53]. Number of Pages: 25. Service: 07/23/2015 by email. Pursuant to ECF-10, filer is directed to file six copies of the brief in paper format. The paper copies of the brief should be received by the court on or before 07/29/2015. [259282] [AT] [Entered: 07/24/2015 01:07 PM] (34) |
| Jul 23, 2015 | 64 | AMICUS BRIEF FILED for Biotechnology Industry Organization [56]. Number of Pages: 12. Service: 07/23/2015 by email. Pursuant to ECF-10, filer is directed to file six copies of the brief in paper format. The paper copies of the brief should be received by the court on or before 07/29/2015. [259283] [AT] [Entered: 07/24/2015 01:08 PM] (18) |
| Jul 23, 2015 | 65 | AMICUS BRIEF FILED for Pharmaceutical Research and Manufacturers of America [61]. Number of Pages: 24. Service: 07/23/2015 by email. Pursuant to ECF-10, filer is directed to file six copies of the brief in paper format. The paper copies of the brief should be received by the court on or before 07/29/2015. [259285] [AT] [Entered: 07/24/2015 01:16 PM] (33) |
| Jul 21, 2015 | 45 | 6 paper copies of the Opening Response Brief [44] received from Appellee Astrazeneca AB. [258136] [AT] [Entered: 07/21/2015 03:07 PM] (0) |
| Jul 16, 2015 | 43 | TENDERED from Appellee Astrazeneca AB. Title: RESPONSE BRIEF. Service: 07/16/2015 by email. [257045] [Kannon Shanmugam] [Entered: 07/16/2015 06:31 PM] (75) |
| Jul 16, 2015 | 44 | BRIEF FILED for Appellee Astrazeneca AB [43]. Number of Pages: 61. Service: 07/16/2015 by email. Pursuant to ECF-10, filer is directed to file six copies of the brief in paper format. The paper copies of the brief should be received by the court on or before 07/22/2015. Appellant Mylan Pharmaceuticals Inc. reply brief is due 08/10/2015 per the court's prior order. [257190] [AT] [Entered: 07/17/2015 11:09 AM] (75) |
| Jul 15, 2015 | 42 | Entry of appearance for David M. Krinsky as of counsel for Appellee Astrazeneca AB. Service: 07/15/2015 by email. [256338] [David Krinsky] [Entered: 07/15/2015 03:07 PM] (2) |
| Jul 1, 2015 | 41 | ORDER granting motion to withdraw attorney C. Harker Rhodes IV [40] filed by Appellant Mylan Pharmaceuticals Inc. Service as of this date by Clerk of Court. [252957] [AT] [Entered: 07/01/2015 02:39 PM] (2) |
| Jun 30, 2015 | 40 | MOTION of Appellant Mylan Pharmaceuticals Inc. to withdraw counsel C. Harker Rhodes IV. Response/Opposition is due 07/13/2015 [Consent: not addressed]. Service: 06/30/2015 by email. [252390] [C. Harker Rhodes] [Entered: 06/30/2015 09:55 AM] (2) |
| Jun 26, 2015 | 38 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.4(a), Fed. Cir. R. 47.3 and ECF-2(E) to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [251637] [IW] [Entered: 06/26/2015 07:39 AM] (0) |
| Jun 26, 2015 | 39 | Amended Certificate of Interest for the Appellee Astrazeneca AB. Service: 06/26/2015 by email. [251880] [Kannon Shanmugam] [Entered: 06/26/2015 03:40 PM] (3) |
| Jun 24, 2015 | 37 | ORDER granting motion to extend time to file appellee's principal brief [34] and granting motion to extend time to file appellant's reply brief [34] filed by Appellee Astrazeneca AB and Appellant Mylan Pharmaceuticals Inc. The appellee's principal brief is due July 16, 2015, and the appellant's reply brief is due August 10, 2015. Service: 06/24/2015 by clerk. [251187] [LMS] [Entered: 06/24/2015 03:40 PM] (2) |
| Jun 17, 2015 | 34 | MOTION of Appellant Mylan Pharmaceuticals Inc. and Appellee Astrazeneca AB to extend the time to 07/16/2015 at 11:59 pm to file the appellee/respondent/cross-appellant's principal brief. Response/Opposition is due 07/02/2015, to extend the time to 08/10/2015 at 11:59 pm to file the reply brief. Response/Opposition is due 07/02/2015 [Consent: unopposed]. Service: 06/17/2015 by email. [249022] [Kannon Shanmugam] [Entered: 06/17/2015 12:32 AM] (9) |
| Jun 17, 2015 | 35 | Notice to counsel for Amicus Curiae Generic Pharmaceutical Association: The record of this case indicates that the Certificate of Interest has not been filed. A completed certificate of Interest must be submitted in accordance with Fed. Cir. R. 47.4. Service as of this date by Clerk of Court. [249039] [AT] [Entered: 06/17/2015 08:41 AM] (0) |
| Jun 17, 2015 | 36 | Certificate of Interest for the Amicus Curiae Generic Pharmaceutical Association. Service: 06/17/2015 by email. [249169] [James Wallace] [Entered: 06/17/2015 10:26 AM] (2) |
| Jun 15, 2015 | 33 | Certificate of Interest for the Amicus Curiae Chamber of Commerce of the United States of America. Service: 06/15/2015 by email. [248571] [Andrew Pincus] [Entered: 06/15/2015 05:27 PM] (2) |
| Jun 1, 2015 | 32 | 6 paper copies of the amicus Brief [31], amicus Brief [30] received from Amici Curiae Chamber of Commerce of the United States of America and Generic Pharmaceutical Association. [244920] [AT] [Entered: 06/01/2015 03:21 PM] (0) |
| May 28, 2015 | 0 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: Notice regarding the ECF account(s) of Mr. Eric Harold Weisblatt for Generic Pharmaceutical Association. One or more e-mail addresses associated with your CM/ECF account, (ccitro@wileyrein.com), is invalid and has been returned as undeliverable. Pursuant to ECF-2(E) of the Administrative Order Regarding Electronic Case Filing, an ECF filer must update all contact information with the Pacer Service Center. [244213] [IW] [Entered: 05/28/2015 10:31 AM] (0) |
| May 26, 2015 | 20 | Entry of appearance for James H. Wallace, Jr. as principal counsel for Generic Pharmaceutical Association. Service: 05/26/2015 by email. [243497] [James Wallace] [Entered: 05/26/2015 03:00 PM] (2) |
| May 26, 2015 | 21 | Entry of appearance for Eric H. Weisblatt as of counsel for Generic Pharmaceutical Association. Service: 05/26/2015 by email. [243499] [James Wallace] [Entered: 05/26/2015 03:01 PM] (2) |
| May 26, 2015 | 22 | Entry of appearance for Mark A. Pacella as of counsel for Generic Pharmaceutical Association. Service: 05/26/2015 by email. [243500] [James Wallace] [Entered: 05/26/2015 03:02 PM] (2) |
| May 26, 2015 | 23 | Entry of appearance for A. Claire Frezza as of counsel for Generic Pharmaceutical Association. Service: 05/26/2015 by email. [243502] [James Wallace] [Entered: 05/26/2015 03:03 PM] (2) |
| May 26, 2015 | 24 | TENDERED from Generic Pharmaceutical Association Title: AMICUS CURIAE BRIEF. Service: 05/26/2015 by email. [243508] [James Wallace] [Entered: 05/26/2015 03:07 PM] (23) |
| May 26, 2015 | 25 | Entry of appearance for Andrew J. Pincus as principal counsel for The Chamber of Commerce of the United States. Service: 05/26/2015 by email. [243712] [Andrew Pincus] [Entered: 05/26/2015 07:55 PM] (2) |
| May 26, 2015 | 26 | Entry of appearance for Paul W. Hughes as of counsel for The Chamber of Commerce of the United States. Service: 05/26/2015 by email. [243717] [Paul Hughes] [Entered: 05/26/2015 08:00 PM] (2) |
| May 26, 2015 | 27 | Entry of appearance for James F. Tierney as of counsel for The Chamber of Commerce of the United States. Service: 05/26/2015 by email. [243719] [James Tierney] [Entered: 05/26/2015 08:05 PM] (2) |
| May 26, 2015 | 28 | Entry of appearance for Kate Comerford Todd as of counsel for The Chamber of Commerce of the United States. Service: 05/26/2015 by email. [243722] [Kathryn Todd] [Entered: 05/26/2015 08:12 PM] (2) |
| May 26, 2015 | 29 | TENDERED from The Chamber of Commerce of the United States Title: AMICUS CURIAE BRIEF. Service: 05/26/2015 by email. [243730] [Andrew Pincus] [Entered: 05/26/2015 08:22 PM] (34) |
| May 26, 2015 | 30 | AMICUS BRIEF FILED for Generic Pharmaceutical Association [24]. Number of Pages: 16. Service: 05/26/2015 by email. Pursuant to ECF-10, filer is directed to file six copies of the brief in paper format. The paper copies of the brief should be received by the court on or before 06/01/2015. [243815] [SW] [Entered: 05/27/2015 09:27 AM] (23) |
| May 26, 2015 | 31 | AMICUS BRIEF FILED for Chamber of Commerce of the United States of America [29]. Number of Pages: 23. Service: 05/26/2015 by email. Pursuant to ECF-10, filer is directed to file six copies of the brief in paper format. The paper copies of the brief should be received by the court on or before 06/01/2015. [243818] [SW] [Entered: 05/27/2015 09:29 AM] (34) |
| May 20, 2015 | 18 | Note to file: Appeals 15-1460 and 15-1456 appear to be related. These cases shall be considered companion cases and assigned to the same merits panel for oral argument. [242274] [15-1460, 15-1456] [AT] [Entered: 05/20/2015 11:32 AM] (0) |
| May 20, 2015 | 19 | 6 paper copies of the Opening Brief [17] received from Appellant Mylan Pharmaceuticals Inc. [242283] [AT] [Entered: 05/20/2015 11:42 AM] (0) |
| May 18, 2015 | 16 | TENDERED from Appellant Mylan Pharmaceuticals Inc.. Title: OPENING BRIEF. Service: 05/18/2015 by email. [241778] [Paul Clement] [Entered: 05/18/2015 07:02 PM] (83) |
| May 18, 2015 | 17 | BRIEF FILED for Appellant Mylan Pharmaceuticals Inc. [16]. Number of Pages: 50. Service: 05/18/2015 by email. Pursuant to ECF-10, filer is directed to file six copies of the brief in paper format. The paper copies of the brief should be received by the court on or before 05/26/2015. Appellee Astrazeneca AB brief is due 07/02/2015. [241802] [AT] [Entered: 05/19/2015 08:26 AM] (83) |
| Apr 16, 2015 | 14 | Entry of appearance for Katherine Moran Meeks as of counsel for Appellee Astrazeneca AB. Service: 04/16/2015 by email. [233311] [Katherine Meeks] [Entered: 04/16/2015 10:52 AM] (3) |
| Apr 16, 2015 | 15 | Entry of appearance for Amy Mason Saharia as of counsel for Appellee Astrazeneca AB. Service: 04/16/2015 by email. [233561] [Amy Saharia] [Entered: 04/16/2015 05:17 PM] (2) |
| Mar 30, 2015 | 10 | Certificate of Interest for the Appellee Astrazeneca AB. Service: 03/28/2015 by email. [227799] [Kannon Shanmugam] [Entered: 03/28/2015 10:27 PM] (3) |
| Mar 30, 2015 | 11 | Docketing Statement for the Appellee Astrazeneca AB. Service: 03/29/2015 by email. [227801] [Kannon Shanmugam] [Entered: 03/29/2015 11:47 AM] (3) |
| Mar 30, 2015 | 12 | Entry of appearance for C. Harker Rhodes IV as of counsel for Appellant Mylan Pharmaceuticals Inc.. Service: 03/30/2015 by email. [227958] [C. Harker Rhodes] [Entered: 03/30/2015 01:55 PM] (2) |
| Mar 30, 2015 | 13 | Entry of appearance for Douglas H. Carsten as of counsel for Appellant Mylan Pharmaceuticals Inc.. Service: 03/30/2015 by email. [228005] [Douglas Carsten] [Entered: 03/30/2015 03:08 PM] (2) |
| Mar 27, 2015 | 8 | Certificate of Interest for the Appellant Mylan Pharmaceuticals Inc.. Service: 03/27/2015 by email. [227606] [Paul Clement] [Entered: 03/27/2015 10:55 AM] (3) |
| Mar 27, 2015 | 9 | Docketing Statement for the Appellant Mylan Pharmaceuticals Inc.. Service: 03/27/2015 by email. [227607] [Paul Clement] [Entered: 03/27/2015 10:56 AM] (3) |
| Mar 23, 2015 | 5 | Entry of appearance for Kannon K. Shanmugam as principal counsel for Appellee Astrazeneca AB. Service: 03/23/2015 by email. [226426] [Kannon Shanmugam] [Entered: 03/23/2015 05:00 PM] (2) |
| Mar 20, 2015 | 6 | Certified list from the United States District Court for the District of Delaware; appellant's filing fee was paid on 3/19/15. [226571] [AT] [Entered: 03/24/2015 10:19 AM] (36) |
| Mar 20, 2015 | 7 | Filing fee paid in the United States District Court for the District of Delaware on 03/19/2015. [226572] [AT] [Entered: 03/24/2015 10:20 AM] (0) |
| Mar 19, 2015 | 3 | Entry of appearance for Paul D. Clement as principal counsel for Appellant Mylan Pharmaceuticals Inc.. Service: 03/19/2015 by email. [225759] [Paul Clement] [Entered: 03/19/2015 09:16 PM] (2) |
| Mar 19, 2015 | 4 | Entry of appearance for D. Zachary Hudson as of counsel for Appellant Mylan Pharmaceuticals Inc.. Service: 03/19/2015 by email. [225764] [David Hudson] [Entered: 03/19/2015 09:23 PM] (2) |
| Mar 17, 2015 | 1 | Appeal docketed. Received:. [225055]Fee/IFP due on 03/31/2015. Entry of Appearance due 03/31/2015. Certificate of Interest is due on 03/31/2015. Docketing Statement due 04/16/2015. Appellant/Petitioner's brief is due 05/18/2015. [SW] [Entered: 03/17/2015 03:33 PM] (4) |
| Mar 17, 2015 | 2 | Clerk's notice to United States District Court for the District of Delaware: The petition for permission to appeal for Appellant Mylan Pharmaceuticals Inc. has been granted. Please forward to this court the certified list and proof of payment of the filing fee. Service as of this date by Clerk of Court. [225060] [SW] [Entered: 03/17/2015 03:39 PM] (1) |
